BROMOCRIPTINE |
SANDOZ 15-754 |
PARLODEL |
CB-154 |
2-BROMOERGOCRYPTINE |
PLO154 |
2-BROMO-Α-ERGOKRYPTINE |
2-BROMO-ALPHA-ERGOKRYPTIN |
BROMOCRYPTINE |
2-BROMO-Α-ERGOCRYPTINE |
BROMOCRIPTINA |
2-BROMO-ALPHA-ERGOKRYPTINE |
PARLODEL® |
(5'ALPHA)-2-BROMO-12'-HYDROXY-2'-(1-METHYLETHYL)-5'-(2-METHYLPROPYL)-3',6',18-TRIOXOERGOTAMAN |
2-BROMO-Α-ERGOKRYPTIN |
BROMOERGOCRYPTINE |
BROMOERGOCRIPTINE |
(5'ALPHA)-2-BROMO-12'-HYDROXY-5'-ISOBUTYL-2'-ISOPROPYL-3',6',18-TRIOXOERGOTAMAN |
2-BROMO-ALPHA-ERGOCRYPTINE |
BROMOCRIPTINUM |
(5'ALPHA)-2-BROMO-12'-HYDROXY-2'-(1-METHYLETHYL)-5'-(2-METHYLPROPYL)ERGOTAMAN-3',6',18-TRIONE |
drugbank:01200 |
chemidplus:25614-03-3 |
pubchem.compound:31101 |
rxcui:1760 |
chembl:CHEMBL493 |
Drug Class | antiparkinson agents |
Year of Approval | 1978 |
FDA Approval | approved |
Drug Class | Small Molecule |
Drug Indications | antidiabetic |
Drug Categories | anti-parkinson drugs |
Drug Categories | adrenergic agonists |
Drug Categories | adrenergic alpha-1 receptor agonists |
Drug Categories | adrenergic alpha-1 receptor antagonists |
Drug Categories | adrenergic alpha-2 receptor agonists |
Drug Categories | adrenergic alpha-agonists |
Drug Categories | adrenergic alpha-antagonists |
Drug Categories | adrenergic antagonists |
Drug Categories | agents producing tachycardia |
Drug Categories | agents that produce hypertension |
Drug Categories | antidepressive agents |
Drug Categories | central nervous system depressants |
Drug Categories | cytochrome p-450 cyp3a substrates |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors |
Drug Categories | cytochrome p-450 cyp3a4 inhibitors (strength unknown) |
Drug Categories | cytochrome p-450 enzyme inhibitors |
Drug Categories | cytochrome p-450 substrates |
Drug Categories | ergot alkaloids and derivatives |
Drug Categories | ergot-derivative dopamine receptor agonists |
Drug Categories | genito urinary system and sex hormones |
Drug Categories | heterocyclic compounds, fused-ring |
Drug Categories | p-glycoprotein inhibitors |
Drug Categories | p-glycoprotein substrates |
Drug Categories | prolactine inhibitors |
Drug Categories | serotonin 5-ht2 receptor agonists |
Drug Categories | serotonin agents |
Drug Categories | serotonin receptor agonists |
agonist (activating) |
Specific Action of the Ligand | Full agonist |
Endogenous Drug? | False |
agonist (activating) |
Trial Name | bromocriptine mesylate,Cycloset, Ergoset |
Novel drug target | Established target |
Specific Action of the Ligand | Full agonist |
agonist (activating) |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
agonist (activating) |
Specific Action of the Ligand | Partial agonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
agonist (activating) |
Endogenous Drug? | False |
Specific Action of the Ligand | Antagonist |
agonist (activating) |
Specific Action of the Ligand | Partial agonist |
Endogenous Drug? | False |
agonist (activating) |
Direct Interaction? | True |
Endogenous Drug? | False |
Specific Action of the Ligand | Partial agonist |
antagonist (inhibitory) |
agonist (activating) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
Direct Interaction? | True |
agonist (activating) |
Specific Action of the Ligand | Partial agonist |
Endogenous Drug? | False |
antagonist (inhibitory) |
agonist (activating) |
Specific Action of the Ligand | Antagonist |
Endogenous Drug? | False |
agonist (activating) |
Specific Action of the Ligand | Partial agonist |
Endogenous Drug? | False |
agonist (activating) |
Specific Action of the Ligand | Partial agonist |
Endogenous Drug? | False |
agonist (activating) |
Specific Action of the Ligand | Partial agonist |
Endogenous Drug? | False |
agonist (activating) |
Specific Action of the Ligand | Full agonist |
Endogenous Drug? | False |
BROMOCRIPTINE | DrugBank Drug Name |
25614-03-3 | CAS Number |
Apo-Bromocriptine | Drug Brand |
Drug Type | small molecule |
Drug Groups | approved |
Drug Groups | investigational |
BROMOCRIPTINE | Primary Drug Name |
Year of Approval | 1978 |
Drug Class | antiparkinson agents |
Drug Indications | antidiabetic |
Drug Class | Small Molecule |
FDA Approval | approved |
C317 | NCI drug code |
CHEMBL493 | ChEMBL Drug ID |
D06YFA | TTD Drug ID |
BROMOCRIPTINE | GuideToPharmacology Ligand Name |